Docmorris
DocMorris, officially known as DocMorris GmbH, is a leading online pharmacy headquartered in Germany. Established in 2000, the company has significantly transformed the pharmaceutical landscape, particularly in the German market, where it operates extensively. Specialising in prescription and over-the-counter medications, DocMorris distinguishes itself through its commitment to customer convenience and accessibility, offering a seamless online shopping experience. The company has achieved notable milestones, including being one of the first online pharmacies to receive a pharmacy licence in Germany, solidifying its market position. With a focus on health and wellness, DocMorris provides a wide range of products, including beauty and personal care items, making it a one-stop solution for consumers. Its innovative approach and dedication to quality have earned it a reputable standing in the competitive online pharmacy industry.
DitchCarbon Score
How does Docmorris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Docmorris's score of 68 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Docmorris's reported carbon emissions
In 2024, Docmorris reported total carbon emissions of approximately 9,823,000 kg CO2e. This figure includes 667,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Scope 2 emissions, related to the generation of purchased electricity, steam, heating, and cooling, accounted for about 192,000 kg CO2e. The majority of emissions, approximately 8,964,000 kg CO2e, fell under Scope 3, which includes indirect emissions from the value chain, such as business travel and downstream transportation. Comparatively, in 2023, total emissions were about 11,391,000 kg CO2e, indicating a significant reduction in emissions year-on-year. The company aims to reduce its Scope 1 and 2 emissions by 4.2% annually, using 2022 as the base year, and has set a long-term goal to achieve net zero emissions for these scopes by 2050. Additionally, Docmorris is committed to a 25% reduction in total emissions by 2030, again using 2022 as the baseline. Docmorris's climate strategy includes ambitious targets to reduce emissions intensity, aiming for an 85% reduction in Scope 1 and 2 emissions per net revenue by 2030, and a 99% reduction by 2050. These commitments reflect the company's proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 81,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 3,031,000 | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | 4,971,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Docmorris is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
